Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2026
Business Overview: InMed is a pharmaceutical drug development company focused on proprietary small molecule drug candidates targeting the endocannabinoid system (CB1 and CB2 receptors). The company's pipeline includes INM-901 (Alzheimer's disease), INM-089 (dry Age-related Macular Degeneration), and INM-755 (Epidermolysis Bullosa).
Strategic Shift: On March 4, 2026, the Board approved the wind-down of BayMedica, the company's only revenue-generating commercial operations segment. As of June 30, 2026, BayMedica had ceased operating activities. The company is now focused solely on preclinical development pending additional financing or a strategic transaction.
Key Financial Metrics
| Metric | Year Ended June 30, 2026 | Year Ended June 30, 2025 |
|---|---|---|
| Net Loss (Continuing Operations) | $(11.37) million | $(8.69) million |
| Net Loss (Discontinued Operations) | $(1.19) million | $0.53 million (Income) |
| Total Net Loss | $(12.56) million | $(8.16) million |
| Research & Development Expenses | $3.03 million | $2.82 million |
| General & Administrative Expenses | $6.66 million | $5.41 million |
| Impairment Charges (Fixed & Intangible Assets) | $1.65 million | $0 |
| Cash, Cash Equivalents & Short-term Investments | $2.20 million | $10.78 million |
| Accumulated Deficit | $(130.23) million | $(117.24) million |
| Net Cash Used in Operating Activities | $(8.64) million | $(8.10) million |
Material Changes vs. Prior Period
- Discontinued Operations: The BayMedica commercial segment, which previously generated revenue, was classified as discontinued operations. This resulted in a shift from $0.53 million of income in 2025 to a $1.19 million loss in 2026 due to wind-down costs and lower gross profit.
- Impairment Charges: The company recorded $1.65 million in impairment charges in 2026 ($1.46 million for intangible assets and $0.19 million for fixed assets) compared to none in 2025, reflecting the reduced value of assets following the business pivot.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $8.5 million year-over-year, dropping from $10.78 million to $2.20 million.
- Operating Expenses: Total operating expenses for continuing operations increased by 37% to $11.61 million, driven by higher G&A costs and the aforementioned impairments.
Guidance, Outlook, and Risks
Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the report issuance. The $2.2 million cash balance is estimated to fund operations only into the third quarter of calendar 2026.
Strategic Transactions:
- Merger with Mentari Therapeutics: InMed entered into a Merger Agreement with Mentari Therapeutics, Inc. in May 2026. If consummated, pre-Merger InMed shareholders would own approximately 1.01% of the combined company. The transaction is subject to closing conditions, including Mentari securing $150 million in pre-closing financing.
- Financing Needs: If the merger fails, the company must raise additional capital through equity or debt financings to continue R&D. There is no assurance such funding will be available.
Key Risks:
- Delisting: The company received a Nasdaq deficiency notice in March 2026 regarding the minimum bid price rule but regained compliance in June 2026. Future failure to meet listing standards could lead to delisting.
- Legal Proceedings: BayMedica is involved in arbitration with a third-party licensor regarding a technology license agreement. The licensor seeks approximately $3.4 million in past payments and $2.3 million annually for the remainder of the term. An unfavorable outcome could materially impact the company.
- Regulatory & Development: All product candidates are in preclinical stages. Success depends on regulatory approval, clinical trial results, and the ability to scale manufacturing.
Investor Verification Checklist
- Cash Runway: Verify current cash balance and burn rate to confirm if the company can operate beyond Q3 2026 without new capital.
- Merger Status: Monitor the status of the Mentari Therapeutics merger and the $150 million financing condition required for closing.
- Arbitration Outcome: Track the "Patent License Matter" arbitration; a loss could trigger significant cash outflows ($5.7 million+).
- Nasdaq Compliance: Confirm continued compliance with Nasdaq listing requirements, specifically the minimum bid price and market value rules.
- Capital Raises: Review any subsequent filings for equity offerings or debt financings intended to address the going concern uncertainty.